Special Issues
Table of Content

Advances in Skin Cancer Management: From Molecular Targets to Innovative Treatments

Submission Deadline: 31 December 2025 (closed) View: 897 Submit to Journal

Guest Editor(s)

Dr. Mara Mădălina Mihai

Email: mara.mihai@umfcd.ro

Affiliation: 1. Department of Oncological Dermatology, Elias Emergency University Hospital, Bucharest, 011461, Romania

2. Department of Dermatology, Carol Davila University of Medicine and Pharmacy, Bucharest, 020021, Romania

Homepage:

Research Interests: dermatology; microbiology; skin cancer; melanoma; nanotechnology; targeted therapy; skin healing; chronic wounds; bacterial biofilms; bacterial pathogenesis;  host-microbiome interactions; antibacterial therapies

图片3.png


Dr. Alina-Maria Holban

Email: alina.m.holban@bio.unibuc.ro

Affiliation: 1. Department of Microbiology and Immunology, Faculty of Biology, University of Bucharest, Bucharest, 060101, Romania 

2. The Research Institute of the University of Bucharest, Bucharest, 060023, Romania

Homepage:

Research Interests: microbiology; immunology; new antimicrobial agents; host-pathogen signaling; infection control; antimicrobial nanomaterials; bacterial pathogenesis; virulence factors; quorum sensing; biofilms; antibacterial activity; antibiotic resistance; Staphylococcus aureus; Escherichia coli; Pseudomonas aeruginosa; microbial molecular biology; bioactive materials; nanotechnology; nanoengineering

图片4.png


Summary

Despite increasing public awareness and scientific interest in skin cancer risks, the incidence of both melanoma and non-melanoma skin cancers (basal cell carcinoma, squamous cell carcinoma) continues to rise rapidly. Recent research breakthroughs have provided valuable insights into the genetic and molecular landscape, as well as the role of the host-microbiome interplay in the development and treatment response of skin cancer. These discoveries have led to significant therapeutic innovations. However, resistance mechanisms remain a persistent challenge, emphasizing the need for personalized treatment approaches, combined therapies, and ongoing research to achieve lasting therapeutic outcomes. As an editorial team with expertise in clinical care and innovative therapeutics—such as drug delivery systems, nanotechnology, transdermal drug delivery systems, immunotherapy, and cold plasma—we are excited to invite you to submit your recent work to this Special Issue. Our goal is to showcase the most groundbreaking and promising developments in the management of skin cancer, from molecular targets to innovative treatments, highlighting the transformative effects of these advancements on clinical practice. 


Keywords

skin cancer; Melanoma; non-melanoma skin cancer; basal cell carcinoma; squamous cell carcinoma; molecular targets; host-microbiome interplay; targeted therapy; precision medicine; drug delivery systems; nanotechnology; transdermal drug delivery; immunotherapy; cold plasma; vaccines; drug delivery systems; nanotechnology; bioactive materials

Published Papers


  • Open Access

    REVIEW

    EZH2 in Acral Lentiginous Melanoma: Molecular, Epigenetic, and Therapeutic Perspectives

    Daniel Arcuschin de Oliveira, Melissa Yoshimi Sakamoto Maeda Nisimoto, Jaciara Moreira Sodré Hunnicutt, Eduarda Massa Sartori, Amanda Fáris Marques, Francisco Macedo Paschoal, Luciana Cavalheiro Marti, Miriam Galvonas Jasiulionis, Miguel Sabino Neto, Renato Santos de Oliveira Filho
    Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.077913
    (This article belongs to the Special Issue: Advances in Skin Cancer Management: From Molecular Targets to Innovative Treatments)
    Abstract Acral lentiginous melanoma (ALM) is characterized by a low mutational burden, frequent chromosomal rearrangements, and profound epigenetic dysregulation, distinguishing it from ultraviolet (UV)-induced melanoma. Among the epigenetic regulators, Enhancer of Zeste Homolog 2 (EZH2), the catalytic component of the Polycomb Repressive Complex 2 (PRC2), plays a central role in chromatin compaction and transcriptional repression through trimethylation of histone H3 on lysine 27 (H3K27me3). EZH2 overexpression or hyperactivation contributes to tumor progression, immune evasion, and therapeutic resistance. Recent multi-omic studies have highlighted the importance of EZH2 in regulating melanoma plasticity, immune modulation, and metabolic reprogramming. In… More >

    Graphic Abstract

    EZH2 in Acral Lentiginous Melanoma: Molecular, Epigenetic, and Therapeutic Perspectives

  • Open Access

    REVIEW

    Epigenetics of Malignant Melanoma: Mechanisms, Diagnostic Approaches and Therapeutic Applications

    Sophiette G. Hong, George F. Murphy, Christine G. Lian
    Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.073894
    (This article belongs to the Special Issue: Advances in Skin Cancer Management: From Molecular Targets to Innovative Treatments)
    Abstract Malignant melanoma (MM) is a highly aggressive skin cancer known for its rapid progression, potential for metastasis, and resistance to treatment. Despite advances in targeted therapies and immunotherapy, the prognosis for metastatic melanoma remains unfavorable. Recent research has shed light on the significance of epigenetic modifications in the pathogenesis of melanoma, revealing critical mechanisms of melanoma development and progression. Epigenetic modifications, including DNA and RNA modifications, histone modifications, chromatin remodeling, and non-coding RNA regulation, disrupt normal gene expression without modifying the DNA sequence, leading to cellular transformation, invasion, immune evasion, and therapeutic resistance. The reversible… More >

Share Link